You will automatically be redirected in 10 seconds. Or, you can click the link below:

https://www.streetinsider.com/Globe+Newswire/Alector+Announces+Achievement+of+Target+Enrollment+in+the+Pivotal+INFRONT-3+Phase+3+Clinical+Trial+of+Latozinemab+in+Individuals+with+Frontotemporal+Dementia+Due+to+a+Progranulin+Gene+Mutation+%28FTD-GR/22322351.html